Soligenix Raises $7.5 Million in Public Offering to Advance Rare Disease Pipeline
Key Insights
Soligenix priced a public offering of 5.56 million shares and warrants at $1.35 per unit, raising approximately $7.5 million in gross proceeds.
The late-stage biopharmaceutical company will use funds for research and development activities, commercialization efforts, and general corporate purposes.
The company's pipeline includes HyBryte for cutaneous T-cell lymphoma (search) treatment and vaccine candidates for biodefense applications.
Soligenix, Inc., a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs, announced the pricing of a $7.5 million public offering on September 26, 2025. The company sold 5,555,560 shares of common stock and accompanying warrants at a combined purchase price of $1.35 per unit.
Offering Structure and Terms
The warrants included in the offering will have an exercise price of $1.35 per share, become exercisable immediately upon issuance, and expire five years from the issuance date. The offering is expected to close on or about September 29, 2025, subject to customary closing conditions.
A.G.P./Alliance Global Partners (search) served as the sole placement agent for the transaction, which was conducted as a "reasonable best efforts" offering with existing and certain healthcare-focused institutional investors.
Warrant Amendment Strategy
As part of the offering structure, Soligenix agreed to amend existing warrants issued in May 2023, April 2024, and July 2024. These existing warrants, which collectively cover 1,162,064 shares of common stock, will have their exercise price reduced to $1.35 per share and their expiration dates aligned with the new warrants being issued in the current offering.
Therapeutic Pipeline Focus
Soligenix operates through two primary business segments. The Specialized BioTherapeutics segment is advancing HyBryte (SGX301), a synthetic hypericin sodium-based photodynamic therapy utilizing safe visible light for treating cutaneous T-cell lymphoma (search) (CTCL). The company has completed a successful Phase 3 study and is conducting a second Phase 3 trial, with regulatory approvals planned to support potential worldwide commercialization.
The pipeline also includes SGX302, an expansion of synthetic hypericin into psoriasis (search) treatment, and dusquetide (SGX942), a first-in-class innate defense regulator technology for inflammatory diseases including oral mucositis (search) in head and neck cancer patients. Additionally, SGX945 is being developed for Behçet's Disease (search) treatment.
Public Health Solutions Portfolio
The company's Public Health Solutions segment encompasses vaccine development programs supported by government funding. This includes RiVax, a ricin toxin vaccine candidate, and vaccine programs targeting filoviruses such as Marburg and Ebola. The segment also features CiVax, a COVID-19 (search) vaccine candidate for SARS-CoV-2 prevention.
These vaccine programs incorporate Soligenix's proprietary ThermoVax heat stabilization platform technology. Development efforts have received support through government grants and contracts from the National Institute of Allergy and Infectious Diseases (NIAID (search)), Defense Threat Reduction Agency (DTRA (search)), and Biomedical Advanced Research and Development Authority (BARDA (search)).
Financial Strategy and Use of Proceeds
The company intends to allocate the net proceeds from the offering toward research and development activities, commercialization efforts, working capital requirements, and general corporate purposes. The gross proceeds of approximately $7.5 million will be reduced by placement agent fees and other estimated offering expenses.
The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-290413) filed with the Securities and Exchange Commission on September 19, 2025, which became effective on September 25, 2025.